---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024446"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:06:02.071585+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kezar Q3 net loss $17.8M; positive lupus nephritis data and FDA IND clearance

## Summary
- Net loss $17.8M ($0.25/share) vs $14.5M in Q3 2021; operating expenses rose to $18.9M.
- Cash $290.4M at Sept 30, up from $208.4M at Dec 31, 2021, driven by ATM proceeds.
- MISSION Phase 2 lupus nephritis: ORR 64.7% at week 25, 88.2% at week 37; CRR 35.3% then 41.2%.
- FDA cleared IND for zetomipzomib in autoimmune hepatitis; PORTOLA Phase 2a trial to start.
- Preclinical KZR-540, an oral PD-1 expression blocker, presented at SITC on Nov 11.

## SEC filing metadata
- accession: 0000950170-22-024446
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017022024446/0000950170-22-024446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017022024446/kzr-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024446
- JSON: https://secwatch.observer/filing/0000950170-22-024446.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024446.txt

## Key facts
- Earnings Releases
  Kezar Life Sciences, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: Kezar Life Sciences Reports Third Quarter 2022 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000095017022024446/0000950170-22-024446-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.